Stock comparison
IDEXX Laboratories
Zimmer Biomet Holdings
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
ZBH
Zimmer Biomet Holdings
Market cap
$16.54B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | ZBH | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 60D | IDXX |
| Benjamin Graham | 80A | 57C | IDXX |
| Philip Fisher | 75B | 55C | IDXX |
| Peter Lynch | 71B | 44D | IDXX |
| Joel Greenblatt | 83C | 32F | IDXX |
| Charlie Munger | 87A | 50D | IDXX |
| Terry Smith | 84A | 54D | IDXX |
Side-by-side metrics
| Metric | IDXX | ZBH |
|---|---|---|
| Market cap | $44.12B | $16.54B |
| P/E (TTM) | 39.0x | 21.4x |
| EV/EBIT | 31.6x | 17.1x |
| ROIC (TTM) | 40.66% | 4.98% |
| Gross margin | 62.05% | 70.03% |
| Net margin | 24.63% | 9.05% |
| Revenue CAGR 5y | 7.56% | 4.79% |
| EPS CAGR 5y | 10.79% | 16.54% |
| Debt / Equity | 0.7x | 0.5x |
| Dividend yield | 0.0% | 1.15% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- ROIC (TTM)40.66%vs 4.98%+88%
- Net margin24.63%vs 9.05%+63%
- Market cap$44.12Bvs $16.54B+63%
- Revenue CAGR 5y7.56%vs 4.79%+37%
ZBH leads on
- Dividend yield1.15%vs 0.0%+100%
- EV/EBIT17.1xvs 31.6x+46%
- P/E (TTM)21.4xvs 39.0x+45%
- EPS CAGR 5y16.54%vs 10.79%+35%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.